Saturday 17 October 2026 Export LGVN’s income statement to Excel — free account

Longeveron Inc.

Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.18%, EPS grew 42.4% and free cash flow fell 49.1%, each against the same quarter a year earlier.

1.39 0.11 −7.33%

Follow LGVN

Alert me

Market cap: $4.8M
P/E: 0.0×
Fwd P/E: −1.1×
Dividend yield: —
F-score: 3/9
Altman Z: −24.10
Beneish M: −3.83
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.65%

Capital & Financial Ratios $m

Market Cap 4.79

Revenue 1.19

Net Income (23.47)

Free Cash Flow (20.84)

Net Debt (10.08)

Current Ratio 2.63

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.07)

P/S ratio 3.67

P/B ratio 0.42

Past 5Y EPS Growth —

This Y EPS Growth 39.92%

Next Y EPS Growth 35.48%

Next Y revenue growth 46.12%

Next 5Y EPS Growth 58.83%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.54%

10-year low 10-year high

P/B against its own 10 years 0.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	19	5	10
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	6	20	5	11

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	0
	4	3	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	—	(26.60%)	(0.63%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	23.73%	(34.83%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	1
’24	1	0	1	1	2
’23	0	0	0	0	1
’22	0	0	0	0	1
’21	0	0	0	0	1
’20	2	1	2	1	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(6)	—	—	—
’25	(5)	(4)	(5)	(5)	(19)
’24	(3)	(5)	(3)	(3)	(14)
’23	(6)	(5)	(5)	(4)	(19)
’22	(4)	(3)	(4)	(2)	(14)
’21	(3)	(3)	(2)	(1)	(10)
’20	0	(1)	0	(1)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(6)	—	—	—
’25	(5)	(4)	(5)	(5)	(19)
’24	(3)	(5)	(3)	(3)	(15)
’23	(6)	(5)	(5)	(4)	(20)
’22	(4)	(3)	(5)	(2)	(15)
’21	(3)	(3)	(2)	(2)	(11)
’20	(1)	(1)	0	(1)	(3)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.90)	(1.90)	—	—	—
’25	(3.40)	(3.30)	(3.90)	(2.20)	(12.90)
’24	(16.10)	(18.30)	(3.40)	7.66	(26.20)
’23	(22.00)	(27.00)	(28.00)	(25.00)	(102.00)
’22	(17.00)	(27.00)	(25.00)	(21.00)	(90.00)
’21	(18.00)	(26.00)	(25.00)	(20.00)	(90.00)
’20	—	(7.61)	(5.85)	(9.76)	(23.22)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	284.00	280.00	115.00	7.71	4.92	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	4,500.00	1,677.00	457.90	143.00	22.40
People
People	Employees	—	—	—	12	12	22	21	24	26	38
	Revenue/emp, $m	—	—	0.00	0.47	0.47	0.06	0.06	0.03	0.09	0.03
Income, $m
Income, $m	Revenue	—	—	2	6	6	1	1	1	2	1
	Gross margin, %	—	—	31.88	31.10	32.44	45.18	40.67	31.17	78.76	66.97
	EBT	—	—	(6)	(3)	(4)	(17)	(19)	(21)	(16)	(23)
	EBT margin, %	—	—	(296.83)	(52.49)	(66.10)	(1,305.13)	(1,541.33)	(3,020.17)	(667.77)	(1,893.58)
	Net income	—	0	(6)	(3)	(4)	(17)	(19)	(21)	(16)	(23)
	Depreciation	—	—	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	0.11	0.30	35.14	6.90	5.83	3.26	2.54	0.68
	Earnings	—	—	(0.33)	(0.15)	(23.20)	(90.00)	(90.00)	(102.00)	(26.20)	(12.90)
	Cash flow	—	—	(0.27)	(0.13)	(14.76)	(50.93)	(66.61)	(87.45)	(14.74)	(10.61)
	Capex	—	—	0.00	(0.01)	(1.63)	(6.47)	(4.08)	(3.19)	(1.05)	(0.34)
	Free cash flow	—	—	(0.27)	(0.13)	(16.39)	(57.40)	(70.70)	(90.64)	(15.79)	(10.95)
	Book value	—	—	0.36	0.23	12.22	197.95	97.77	31.02	23.26	3.23
	Shares, m	—	—	19	19	0	0	0	0	1	2
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	21.09	21.09	21.09	174.86	57.83	40.46	6.81	7.42
	P/B	—	—	60.66	60.66	60.66	6.10	3.45	4.26	0.74	1.57
	EV/Sales	—	—	21.02	21.02	21.02	150.02	43.42	34.94	(0.89)	3.68
	EV/FCF	—	—	(45.07)	(45.07)	(45.07)	(17.95)	(3.58)	(1.26)	0.14	(0.23)
Cash, $m
Cash, $m	Operating cash flow	—	—	(5)	(2)	(2)	(10)	(14)	(19)	(14)	(19)
	Capex	—	—	0	0	0	(1)	(1)	(1)	(1)	(1)
	Free cash flow	—	—	(5)	(3)	(3)	(11)	(15)	(20)	(15)	(19)
Balance, $m
Balance, $m	Working capital	—	—	2	0	(2)	33	15	2	17	1
	Total debt	—	—	—	4	0	3	2	1	1	0
	Net debt	—	—	(4)	2	0	(32)	(18)	(4)	(18)	(4)
	Shareholders’ equity	—	—	7	4	2	37	21	7	22	6
Returns, %
Returns, %	ROA	—	—	(120.45)	(28.05)	(37.54)	(65.55)	(53.68)	(112.49)	(130.85)	(126.77)
	ROIC	—	—	0.00	(27.89)	(148.41)	(217.55)	(390.74)	(464.75)	(296.82)	(1,230.29)
	ROE	—	—	(112.56)	(52.58)	(116.24)	(86.50)	(65.00)	(163.05)	(172.02)	(164.75)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CDIO Cardio Diagnostics Holdings, Inc.	$5.2M	— (loss-making)	— (loss-making)	−28.00% (below 0%: shrinking)	n/m	+15.58% (above 0%: growing)	100.00%	(27,742.59%)	Compare
PULM Pulmatrix, Inc.	$5.2M	— (loss-making)	— (loss-making)	−99.86% (below 0%: shrinking)	n/m	+41.26% (above 0%: growing)	100.00%	0.00%	Compare
RVPH Reviva Pharmaceuticals Holdings, Inc.	$5.0M	— (loss-making)	—	—	n/m	+57.80% (above 0%: growing)	—	0.00%	Compare
LGVN Longeveron Inc.	$4.8M	— (loss-making)	— (loss-making)	−9.18% (below 0%: shrinking)	n/m	−49.12% (below 0%: shrinking)	63.41%	(2,150.17%)
XBIO Xenetic Biosciences, Inc.	$4.7M	— (loss-making)	— (loss-making)	+11.99% (above 0%: growing)	n/m	−128.11% (below 0%: shrinking)	100.00%	(147.09%)	Compare
PCSA Heatwurx Inc.	$4.7M	1.6×	—	−64.29% (below 0%: shrinking)	n/m	+20.29% (above 0%: growing)	0.00%	0.00%	Compare
DRMA Dermata Therapeutics, Inc.	$4.5M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	0.00%	0.00%	Compare
ENLV Enlivex Ltd.	$4.5M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%	Compare
NCNA NuCana PLC Sponsored ADR	$4.4M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$4.7M	—	—	−46.14%	—	+28.12%	0.00%	0.00%

All 614 Biotechnology stocks →

Longeveron Inc. (LGVN) key facts

Concern: Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024.
Longeveron Inc. (LGVN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LGVN traded at $1.39, a market capitalization of $4.8 million.
Return on equity was −164.8% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −24.10 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.